Essential Thrombocythemia

Common Name(s)

Essential Thrombocythemia

Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. Myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). In essential thrombocythemia, the body produces too many platelet cells. The signs and symptoms vary from person to person, with up to two-thirds of patients not having any symptoms when the platelet cell count first increases. Signs and symptoms may include significant increased production of megakaryocyte (a cell in the bone marrow that is responsible for making platelets), enlargement of the spleen (splenomegaly), and bleeding and/or clotting episodes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Essential Thrombocythemia" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Essential Thrombocythemia" returned 364 free, full-text research articles on human participants. First 3 results:

Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
 

Author(s): Wenwen Ding, Danni Li, Chao Zhuang, Pingping Wei, Wenfeng Mou, Lei Zhang, Hui Liang, Yong Liu

Journal: Medicine (Baltimore). 2018 Jul;97(27):e11331.

 

The JAK2 V617F mutation is frequently found in ET, while it is rare in de novo AML. ET has a low frequency of leukemic transformation. Both secondary AML (sAML) from ET and AML with JAK2 V617F mutation have poor prognoses. Because of the low incidence of JAK2 mutation in acute myeloid ...

Last Updated: 31 Dec 1969

Go To URL
Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2-positive Essential Thrombocythemia.
 

Author(s): Wei-Bi Chen, Xian-Ling Wang

Journal: Chin. Med. J.. 2018 Mar;131(6):748-750.

 

Last Updated: 31 Dec 1969

Go To URL
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.
 

Author(s): Martin Schalling, Andreas Gleiss, Bettina Gisslinger, Albert Wölfler, Veronika Buxhofer-Ausch, Georg Jeryczynski, Maria-Theresa Krauth, Ingrid Simonitsch-Klupp, Christine Beham-Schmid, Jürgen Thiele, Heinz Gisslinger

Journal:

 

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Essential Thrombocythemia" returned 19 free, full-text review articles on human participants. First 3 results:

Abdominal surgery in patients with essential thrombocythemia: A case report and systematic review of literature.
 

Author(s): Yi Zhu, HongGang Jiang, ZhiHeng Chen, BoHao Lu, JiaMing Wu

Journal: Medicine (Baltimore). 2017 Nov;96(47):e8856.

 

Essential thrombocythemia/thrombocytosis (ET) is characterized by increased bleeding and thrombosis risk during the perioperative period. We report the case of a woman with ET and sigmoid colon cancer, in whom the postoperative course was complicated by anastomotic bleeding. A systematic ...

Last Updated: 31 Dec 1969

Go To URL
Essential thrombocythemia treatment algorithm 2018.
 

Author(s): Ayalew Tefferi, Alessandro M Vannucchi, Tiziano Barbui

Journal:

 

Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. Fortunately, prognosis in ET and PV is relatively good, with median survivals in younger patients ...

Last Updated: 31 Dec 1969

Go To URL
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
 

Author(s): L Falchi, H M Kantarjian, S Verstovsek

Journal: Leukemia. 2017 09;31(9):1845-1854.

 

The molecular characterization of myeloproliferative neoplasms, including essential thrombocythemia (ET), has enabled deeper understanding of their pathogenesis. A driver lesion, namely, Janus kinase (JAK)2V617F, calreticulin (CALR) or myeloproliferative leukemia (MPL) gene mutation ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: Essential Thrombocythemia

 

Last Updated: 24 Jul 2017

Go to URL
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: MPN; Essential Thrombocythemia

 

Last Updated: 24 Jul 2017

Go to URL
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: Polycythemia Vera (PV); Essential Thrombocythemia (ET)

 

Last Updated: 7 Jun 2018

Go to URL